Italia markets close in 8 hours 14 minutes

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
11,81-0,28 (-2,32%)
Al 03:44PM BST. Mercato aperto.
Schermo intero
Chiusura precedente12,09
Aperto11,81
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno11,81 - 11,81
Intervallo di 52 settimane11,81 - 11,81
Volume0
Media VolumeN/D
Capitalizzazione8,348M
Beta (5 anni mensile)0,88
Rapporto PE (ttm)N/D
EPS (ttm)-3,04
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

    - 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS). “We are very pleased to complete enrollment of this Phase 3 study of roxadustat for the treatment of anemia in patients with lower risk MDS,” sa

  • GlobeNewswire

    FibroGen Reports Second Quarter 2022 Financial Results

    Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant roxadustat volume growth in China SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company’s recent developments. “We continue making excellent progress with pamrevlumab across al

  • GlobeNewswire

    FibroGen to Report Second Quarter 2022 Financial Results

    SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relation